naftidrofuryl 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1870	31329-57-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: naftidrofurile nafronyl oxalate nafronyl naftidrofuryl naphtidrofuryl naftidrofuryl oxalate naftidrofuryl hydrogen oxalate	A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors. Molecular weight: 383.53 Formula: C24H33NO3 CLOGP: 5.44 LIPINSKI: 1 HAC: 4 HDO: 0 TPSA: 38.77 ALOGS: -5.78 ROTB: 11

Molecule

Description

Molfile Inchi Smiles

Synonyms:

naftidrofurile
nafronyl oxalate
nafronyl
naftidrofuryl
naphtidrofuryl
naftidrofuryl oxalate
naftidrofuryl hydrogen oxalate

A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.

Molecular weight: 383.53
Formula: C24H33NO3
CLOGP: 5.44
LIPINSKI: 1
HAC: 4
HDO: 0
TPSA: 38.77
ALOGS: -5.78
ROTB: 11

Drug dosage:

Dose	Unit	Route
0.60	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
CL (Clearance)	10.80 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.35 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.98 L/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.20 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	57.29	47.71	44	540	304944	34651403
Lactic acidosis	51.69	47.71	20	564	34752	34921595

Showing 1 to 2 of 2 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	82.84	39.34	59	872	519345	79224112
Lactic acidosis	54.73	39.34	23	908	70336	79673121
Hyperkalaemia	52.85	39.34	26	905	114372	79629085

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C04AX21	CARDIOVASCULAR SYSTEM PERIPHERAL VASODILATORS PERIPHERAL VASODILATORS Other peripheral vasodilators
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018490	Serotonin Agents
MeSH PA	D012702	Serotonin Antagonists
MeSH PA	D014665	Vasodilator Agents